Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Rejects Jevtana Because Of Cost, But Clears ALK Abello's Bee Sting Prophylaxis

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.K.'s cost regulator, NICE, rejects Sanofi's lauded prostate cancer therapy cabazitaxel because it considers it too expensive.

You may also be interested in...

NICE Rules Out Sanofi’s Jevtana On Grounds Of Cost Effectiveness

NICE has turned down Sanofi’s Jevtana for prostate cancer, raising fears in England of a new post-code lottery for cancer drugs and highlighting the different between Germany and England’s health technology assessments.

European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come

It is becoming increasingly clear that NICE and IQWiG have very different concerns on the reimbursement front, but it is only a matter of time before IQWiG gets its teeth into cost-benefit analyses

EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe

While giving it a positive risk/benefit balance, EMA says other anti-arrhythmic medicines should be considered before Sanofi's Multaq, potentially heralding its demise in Europe.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts